Voretigene Neparvovec: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Voretigene Neparvovec. Educational only — not medical advice.
Labeled uses
LUXTURNA (voretigene neparvovec-rzyl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s).
Source: FDA labeling via NIH DailyMed (set 08313a24…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.